Develops drugs for cancer and inflammatory diseases.
Jun 2026Revenue $36.7M/yrExpenses $109M/yr
No trendCash runway ≈ 10 months from Jun 2026
Figures by year
When will Foghorn Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $36.7M and expenses $109M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $30.9M | $117M | −$86.4M |
| Dec 2024 | $22.6M | $125M | −$103M |
| Dec 2023 | $34.2M | $142M | −$108M |
| Dec 2022 | $19.2M | $136M | −$117M |
| Dec 2021 | $1.32M | $102M | −$101M |
| Dec 2020 | $430K | $69.0M | −$68.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.